AVEO News and Press, AVEO Pharmaceuticals Inc. From 05/05/22

AVEO Pharmaceuticals, Inc. (AVEO) Q1 2022 Earnings Conference Call May 05, 2022 8:00 AM ET Company Participants Hans Vitzthum – LifeSci Advisors Michael Bailey – President and Chief Executive Officer Mike Ferraresso – Chief Commercial Officer Erick Lucera – Chief F...

AVEO Pharmaceuticals press release (NASDAQ:AVEO): Q1 GAAP EPS of -$0.30. Revenue of $20.9M. FY22 FOTIVDA U.S. net product revenues expectations of between $100.0M and $110.0M to be achieved. For further details see: AVEO Pharmaceuticals GAAP EPS of -$0.30, revenue of $20.9M

– Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million of FOTIVDA ® (tivozanib) U.S. Net Product Revenue – – Q1 2022 FOTIVDA Prescriptions Increased by 25% Compared With Q4 2021 – – Company Rea...

AVEO Pharmaceuticals (NASDAQ:AVEO) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is -$0.21 and the consensus Revenue Estimate is $20.82M (+984.4% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 ...

AAWW,ABEV,ABUS,ACIW,ADNT,ADT,AGIO,ALDX,ALE,AMCX,AMR,APD,APO,APTV,ARGX,ARW,AUTL,AVEO,BALY,BCE,BCRX,OTCQX:BDRBF,BDX,BERY,BFLY,BLD,BLL,OTC:BLRDF,BUD,BXRX,CAH,CARS,CBRE,CCJ,CCOI,CCRD,CIM,CIO,CMRE,CNCE,CNSL,COMM,COP,CROX,CTHR,CWEN,D,DBRG,DDOG,DEN,DFIN,OTCQX:DLAKF,DLX,DNOW,DTM,OTCQX:EDVMF,ENG,EPAM,...

BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. AVEO’s management team will host a conferen...

AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) traded at a new 52-week high today of $23.40. This new high was reached on above average trading volume as 265.6 million shares traded hands, while the average 30-day volume is approximately 371,000 shares. There is potential upside of 1.2% for sha...

Shares of AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) traded at a new 52-week high today of $23.40. Approximately 265.5 million shares have changed hands today, as compared to an average 30-day volume of 369,000 shares. AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biophar...

AVEO Pharmaceuticals, Inc. (AVEO) Q4 2021 Earnings Conference Call March 14, 2022 8:30 AM ET Company Participants Hans Vitzthum – LifeSci Advisors Michael Bailey – Chief Executive Officer Mike Ferraresso – Chief Commercial Officer Erick Lucera – Chief Financial Off...

Gainers: Volt Information Sciences (NYSE:VOLT) +96%. Red Cat Holdings (OTCQB:RCAT) +46%. Turquoise Hill Resources (NYSE:TRQ) +32%. Zhongchao (NASDAQ:ZCMD) +29%. Mullen Automotive (NASDAQ:MULN) +28%. AgriFORCE Growing Systems (NASDAQ:AGRI) +26%. FirstMark Horizon Acquisition (NYSE:FMAC) +23%. ...